Adicet Bio's Cancer Candidate Shows Anti-Tumor Activity In Preclinical Study

Adicet Bio Inc ACET announced preclinical data highlighting ADI-270, an allogeneic "off-the-shelf" gamma delta CAR T cell therapy candidate targeting CD70+ cancers, at the Annual Meeting of the American Society of Gene & Cell Therapy.

Gamma delta T cells modified to express CD70 CAR were successfully generated and expanded without evident hindrances from CD70-mediated fratricide.

Also Read: Adicet Bio Shares Fall After Underwhelming Data From Non-Hodgkin's Lymphoma Study.

ADI-270 demonstrated preclinical proof-of-concept.

ADI-270 gamma delta 1 CAR T cells expressed a predominant naïve-like memory phenotype with potent in vitro cytotoxicity and production of proinflammatory cytokines against CD70+ tumor cell lines via multiple mechanisms.

ADI-270 showed significant inhibition of tumor growth in CD70+ tumor cell lines, which was maintained in the presence of TGF beta inhibitory factor, and exhibited improved resistance to killing by host T cell rejection.

ADI-270 also demonstrated marked biodistribution and infiltration into solid renal cell carcinoma tumor models.

Price Action: ACET shares are down 6.01% at $6.27 on the last check Thursday.